Objective To evaluate the efficacy of denosumab in suppressing joint destruction when
added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy …

Objective To investigate new bone erosion and cartilage destruction predictors in
rheumatoid arthritis (RA) patients treated with conventional synthetic disease-modifying …

Objective To evaluate the safety and efficacy of long-term denosumab 60 mg every 6 months
(Q6M) or every 3 months (Q3M) in patients with rheumatoid arthritis (RA). Methods This 12 …

抄録 Previously we reported that 8-week treatment with methylprednisolone acetate (MPA:
0.1 mg/kg, sc, 3 days a week) of male rats caused a novel type of osteopenia whose …

Objectives To clarify which rheumatoid arthritis (RA) patients benefit most from the anti-
receptor activator of nuclear factor-κB ligand antibody denosumab to reduce the progression …

抄録 A glucocorticoid-induced osteopenia (GC-OP) model was developed in Wistar male
rats to use for in vivo screening of anti-osteoporotic candidates. 1) Two week treatment with …

抄録 Using an experimental model of type 1 osteoporosis under the chronic therapy with an
anti-inflammatory steroid, the bone anabolic effect of PTH (1-34) was evaluated by …

It was examined histomorphometrically whether or not and how chronic treatment with nasal
salmon calcitonin (SCT) of rats could prevent ovariectomy (OVX)-induced osteoporotic …

抄録 A glucocorticoid-induced osteopenia (GC-OP) model was developed in Wistar male
rats to use for in vivo screening of anti-osteoporotic candidates. 1) Two week treatment with …

Objective To evaluate safety and efficacy of long-term denosumab 60 mg every 6 (Q6M) or 3
months (Q3M) in rheumatoid arthritis (RA) patients. Methods This 12-month, randomised …